Biologic Effective in Patients with Psoriasis
In a study published in American Journal of Clinical Dermatology, researchers analyzed the efficacy of adalimumab (Humira, AbbVie Inc.) in patients with psoriasis who previously received systematic therapy.
To determine the efficacy of adalimumab in patients who previously received systematic therapy, including failed therapy, the researchers performed a pooled post hoc analysis of PASI response data from 3 double-blind, placebo-controlled clinical trials in patients with moderate-to-severe psoriasis.
Patients from M02-528, REVEAL and CHAMPION studies, who had been previously exposed to systematic treatment, were enrolled in the study. The participants were categorized based on their responses from the previous studies. To determine the efficacy of adalimumab, experts analyzed the comparison of adalimumab and placebo at the end of the double-blind treatment period for the overall pooled intent-to-treat population (N=1,469), and subgroups that received previous systematic pretreatments (N=780), or did not respond to to previous systematic pretreatments (N=229).
At week 16, rates for an improvement of ≥75 % from baseline in the PASI score (PASI 75 response) were significantly greater (P<0.001) in patients treated with adalimumab compared with patients who received placebo in the overall (72.1% vs 8.0%, respectively), previously treated (72.7% vs 8.5%, respectively) and previously failed treatment (70.4% vs 8.1%, respectively) groups. PASI 75 response rates were similar in the overall group and in patients who did not respond to methotrexate, cyclosporine or psoralen plus ultraviolet A therapy. Improvements of ≥90% or ≥100% from baseline PASI score were also higher with adalimumab versus placebo in previously treated patients.
Adalimumab was efficacious for the treatment of moderate-to-severe psoriasis regardless of prior exposure to systemic therapies or failure of those prior therapies, concluded the researchers.
Papp KA, Armstrong AW, Reich K, Karunaratne M, Valdecantos W. Adalimumab efficacy in patients with psoriasis who received or did not respond to prior systematic therapy: A pooled hoc analysis of results from three double-blind, placebo-controlled clinical trials. Am J Clin Dermatol. Published online ahead of print November 7, 2015.